1800115-22-3
Chemical Structure
Janagliflozin
- CAS No.: 1800115-22-3
- Formula:C25H29ClO6
- Molecular Weight:460.95
InChIKey: WDBIPGHUEJEKTC-CGTLGCROSA-N
SMILES: [H][C@](C1)(C2)[C@@]1([H])C[C@H]2OC3=CC=C(C=C3)CC4=CC([C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)=CC=C4Cl
Biological Activity: Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Janagliflozin | Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Song L, et al. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor. Clin Pharmacokinet. 2023 Mar;62(3):505-518. [Content Brief]
- [2]. Zhao H, et al. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. Eur J Pharm Sci. 2022 Dec 1;179:106298. [Content Brief]
Keywords
